![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5C1 |
Gene summary for ATP5C1 |
![]() |
Gene information | Species | Human | Gene symbol | ATP5C1 | Gene ID | 509 |
Gene name | ATP synthase F1 subunit gamma | |
Gene Alias | ATP5C | |
Cytomap | 10p14 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P36542 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
509 | ATP5C1 | GSM4909281 | Human | Breast | IDC | 1.23e-14 | -2.90e-01 | 0.21 |
509 | ATP5C1 | GSM4909282 | Human | Breast | IDC | 2.12e-16 | -2.90e-01 | -0.0288 |
509 | ATP5C1 | GSM4909285 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.21 |
509 | ATP5C1 | GSM4909286 | Human | Breast | IDC | 2.75e-14 | -2.90e-01 | 0.1081 |
509 | ATP5C1 | GSM4909287 | Human | Breast | IDC | 4.45e-17 | -2.90e-01 | 0.2057 |
509 | ATP5C1 | GSM4909288 | Human | Breast | IDC | 1.84e-03 | -2.90e-01 | 0.0988 |
509 | ATP5C1 | GSM4909289 | Human | Breast | IDC | 3.55e-02 | -2.90e-01 | 0.1064 |
509 | ATP5C1 | GSM4909290 | Human | Breast | IDC | 4.89e-12 | -2.90e-01 | 0.2096 |
509 | ATP5C1 | GSM4909291 | Human | Breast | IDC | 1.27e-09 | -2.90e-01 | 0.1753 |
509 | ATP5C1 | GSM4909293 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.1581 |
509 | ATP5C1 | GSM4909294 | Human | Breast | IDC | 9.36e-17 | -2.90e-01 | 0.2022 |
509 | ATP5C1 | GSM4909295 | Human | Breast | IDC | 2.06e-07 | -2.90e-01 | 0.0898 |
509 | ATP5C1 | GSM4909296 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.1524 |
509 | ATP5C1 | GSM4909297 | Human | Breast | IDC | 1.81e-17 | -2.90e-01 | 0.1517 |
509 | ATP5C1 | GSM4909298 | Human | Breast | IDC | 4.80e-16 | -2.90e-01 | 0.1551 |
509 | ATP5C1 | GSM4909299 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.035 |
509 | ATP5C1 | GSM4909300 | Human | Breast | IDC | 1.85e-06 | -2.90e-01 | 0.0334 |
509 | ATP5C1 | GSM4909301 | Human | Breast | IDC | 1.81e-17 | -2.90e-01 | 0.1577 |
509 | ATP5C1 | GSM4909302 | Human | Breast | IDC | 7.99e-17 | -2.90e-01 | 0.1545 |
509 | ATP5C1 | GSM4909303 | Human | Breast | IDC | 4.86e-04 | -2.90e-01 | 0.0438 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520810 | Colorectum | CRC | Chemical carcinogenesis - reactive oxygen species | 43/1091 | 223/8465 | 3.96e-03 | 2.36e-02 | 1.60e-02 | 43 |
hsa0520811 | Colorectum | CRC | Chemical carcinogenesis - reactive oxygen species | 43/1091 | 223/8465 | 3.96e-03 | 2.36e-02 | 1.60e-02 | 43 |
hsa0501226 | Endometrium | AEH | Parkinson disease | 115/1197 | 266/8465 | 6.24e-32 | 1.01e-29 | 7.42e-30 | 115 |
hsa0502020 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
hsa0501620 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
hsa0019020 | Endometrium | AEH | Oxidative phosphorylation | 69/1197 | 134/8465 | 5.80e-25 | 3.14e-23 | 2.30e-23 | 69 |
hsa0541525 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa0520826 | Endometrium | AEH | Chemical carcinogenesis - reactive oxygen species | 91/1197 | 223/8465 | 3.28e-23 | 1.33e-21 | 9.76e-22 | 91 |
hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa0501020 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
hsa0471426 | Endometrium | AEH | Thermogenesis | 85/1197 | 232/8465 | 3.44e-18 | 9.33e-17 | 6.83e-17 | 85 |
hsa0502220 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
hsa05012111 | Endometrium | AEH | Parkinson disease | 115/1197 | 266/8465 | 6.24e-32 | 1.01e-29 | 7.42e-30 | 115 |
hsa05020110 | Endometrium | AEH | Prion disease | 110/1197 | 273/8465 | 2.39e-27 | 2.44e-25 | 1.78e-25 | 110 |
hsa05016110 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
hsa00190110 | Endometrium | AEH | Oxidative phosphorylation | 69/1197 | 134/8465 | 5.80e-25 | 3.14e-23 | 2.30e-23 | 69 |
hsa05415111 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa05208112 | Endometrium | AEH | Chemical carcinogenesis - reactive oxygen species | 91/1197 | 223/8465 | 3.28e-23 | 1.33e-21 | 9.76e-22 | 91 |
hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
hsa05010110 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5C1 | SNV | Missense_Mutation | c.196N>T | p.Ala66Ser | p.A66S | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.829) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5C1 | SNV | Missense_Mutation | novel | c.361C>A | p.Leu121Ile | p.L121I | P36542 | protein_coding | tolerated(0.19) | benign(0.027) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5C1 | SNV | Missense_Mutation | novel | c.323C>T | p.Ser108Phe | p.S108F | P36542 | protein_coding | deleterious(0.03) | benign(0.239) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP5C1 | SNV | Missense_Mutation | novel | c.817N>G | p.Leu273Val | p.L273V | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.467) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
ATP5C1 | SNV | Missense_Mutation | novel | c.714C>G | p.Ile238Met | p.I238M | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.852) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ATP5C1 | SNV | Missense_Mutation | rs200847831 | c.829N>T | p.Arg277Cys | p.R277C | P36542 | protein_coding | tolerated(0.06) | possibly_damaging(0.524) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP5C1 | SNV | Missense_Mutation | c.809N>G | p.Lys270Arg | p.K270R | P36542 | protein_coding | tolerated(0.12) | benign(0.076) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
ATP5C1 | SNV | Missense_Mutation | novel | c.518N>C | p.Leu173Ser | p.L173S | P36542 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ATP5C1 | SNV | Missense_Mutation | novel | c.76N>A | p.Ala26Thr | p.A26T | P36542 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP5C1 | SNV | Missense_Mutation | rs758013111 | c.497C>T | p.Ala166Val | p.A166V | P36542 | protein_coding | tolerated(0.1) | benign(0.399) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |